{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:22:42Z","timestamp":1787660562023,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":224,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novo Nordisk Foundation\u2014Investigator Initiated Clinical Trials","award":["NNF20OC0063912"],"award-info":[{"award-number":["NNF20OC0063912"]}]},{"name":"Foundation for Research in Neurology"},{"DOI":"10.13039\/501100008249","name":"Frimodt-Heineke Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008249","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Herlev and Gentofte Hospitals Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cerebral small vessel disease is a major contributor to stroke and cognitive impairment, often associated with reduced cerebral blood flow and cerebrovascular reactivity. In this study, we used MRI to investigate if daily treatment with the phosphodiesterase-5 inhibitor tadalafil over 3 months improved cerebral blood flow and cerebrovascular reactivity in patients with cerebral small vessel disease.<\/jats:p>\n                  <jats:p>Using a randomized, placebo-controlled, parallel-group design, this MRI sub-study was prospectively performed as part of the Effect of Tadalafil in Lacunar Stroke 2 trial, which included a total of 76 participants, of whom 60 were included in the per-protocol analysis. Patients with cerebral small vessel disease and prior stroke or transient ischaemic attack received either tadalafil (20\u2005mg\/day) or placebo for 3 months and completed the study. Neurovascular outcomes were assessed at baseline and at the 3-month follow-up using dual-echo pseudo-continuous arterial spin labelling MRI to evaluate reactivity to hypercapnia and visual stimulation. Endpoints included changes in whole-brain baseline cerebral blood flow and cerebrovascular reactivity, visual stimulation response, and neurovascular coupling index. In addition, we investigated arterial transit time measured using diffusion-prepared pseudo-continuous arterial spin labelling and changes in event-related sensory blood-oxygen-level-dependent responses in the primary somatosensory cortex (S1) after stimulation of the index finger.<\/jats:p>\n                  <jats:p>In total, 60 participants (median age: 66.5, 14 females) were included in this per-protocol sub-study analysis (28 on tadalafil and 32 on placebo). Forty-two pseudo-continuous arterial spin labelling datasets (20 on tadalafil and 22 on placebo), 53 blood-oxygen-level-dependent functional MRI datasets (26 on tadalafil and 27 on placebo), and 45 arterial transit time datasets (22 on tadalafil and 23 on placebo) were of sufficient quality to be included in the analysis. Baseline whole-brain cerebral blood flow was 25.4 \u00b1 5.1\u2005ml\/100\u2005g\/min. Compared to placebo, tadalafil significantly increased whole-brain cerebral blood flow with a mean group difference of 3.33 \u00b1 0.97\u2005ml\/100\u2005g\/min at follow-up (P = 0.001). None of the other MRI-based outcome metrics differed between groups.<\/jats:p>\n                  <jats:p>Three months of tadalafil treatment significantly enhanced whole-brain cerebral blood flow in patients with cerebral small vessel disease without altering cerebrovascular reactivity, neurovascular coupling, arterial transit time, and event-related blood-oxygen-level-dependent responses. The clinical significance of a tadalafil-induced increase in cerebral blood flow remains to be determined in prospective studies covering longer treatment periods.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag309","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:44:46Z","timestamp":1786535086000},"source":"Crossref","is-referenced-by-count":0,"title":["Neurovascular effects of tadalafil in patients with cerebral small vessel disease: ETLAS-2 substudy"],"prefix":"10.1093","volume":"8","author":[{"given":"Joakim","family":"\u00d6lmestig","sequence":"first","affiliation":[{"name":"Neurovascular Research Unit, Department of Neurology, Copenhagen University Hospital\u2014Herlev and Gentofte , Herlev 2730 ,","place":["Denmark"]},{"name":"Danish Research Centre for Magnetic Resonance, Department of Radiology and Nuclear Medicine, Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre 2650 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen 2200 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian N","family":"Mortensen","sequence":"additional","affiliation":[{"name":"Danish Research Centre for Magnetic Resonance, Department of Radiology and Nuclear Medicine, Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre 2650 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Fagerlund","sequence":"additional","affiliation":[{"name":"Child and Adolescent Mental Health Center, Copenhagen University Hospital, Mental Health Services CPH , Hellerup 2900 ,","place":["Denmark"]},{"name":"Department of Psychology, University of Copenhagen , Copenhagen 1353 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Naveed","sequence":"additional","affiliation":[{"name":"Department of Radiology, Copenhagen University Hospital\u2014Herlev and Gentofte , Herlev 2730 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette M","family":"Nordling","sequence":"additional","affiliation":[{"name":"Department of Radiology, Copenhagen University Hospital\u2014Herlev and Gentofte , Herlev 2730 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-3194","authenticated-orcid":false,"given":"Hanne","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen 2200 ,","place":["Denmark"]},{"name":"Department of Neurology, Copenhagen University Hospital\u2014Bispebjerg and Frederiksberg , Copenhagen 2400 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle K","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen 2200 ,","place":["Denmark"]},{"name":"Department of Neurology, Copenhagen University Hospital\u2014Rigshospitalet , Glostrup 2600 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai B","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Copenhagen University Hospital\u2014North Zealand , Hiller\u00f8d 3400 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig R","family":"Siebner","sequence":"additional","affiliation":[{"name":"Danish Research Centre for Magnetic Resonance, Department of Radiology and Nuclear Medicine, Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre 2650 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen 2200 ,","place":["Denmark"]},{"name":"Department of Neurology, Copenhagen University Hospital\u2014Bispebjerg and Frederiksberg , Copenhagen 2400 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4210-0523","authenticated-orcid":false,"given":"Christina","family":"Kruuse","sequence":"additional","affiliation":[{"name":"Neurovascular Research Unit, Department of Neurology, Copenhagen University Hospital\u2014Herlev and Gentofte , Herlev 2730 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen 2200 ,","place":["Denmark"]},{"name":"Department of Brain and Spinal Cord Injury, Neuroscience Centre, Copenhagen University Hospital\u2014Rigshospitalet , Glostrup 2600 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"10","key":"2026082507364619500_fcag309-B1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1177\/0271678X16662891","article-title":"Cerebral blood flow in small vessel disease: A systematic review and meta-analysis","volume":"36","author":"Shi","year":"2016","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7","key":"2026082507364619500_fcag309-B2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(10)70104-6","article-title":"Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges","volume":"9","author":"Pantoni","year":"2010","journal-title":"Lancet Neurol"},{"issue":"2","key":"2026082507364619500_fcag309-B3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1161\/CIRCRESAHA.124.324327","article-title":"Cerebrovascular effects of sildenafil in small vessel disease: The OxHARP trial","volume":"135","author":"Webb","year":"2024","journal-title":"Circ Res"},{"issue":"8","key":"2026082507364619500_fcag309-B4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","article-title":"Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration","volume":"12","author":"Wardlaw","year":"2013","journal-title":"Lancet Neurol"},{"key":"2026082507364619500_fcag309-B5","doi-asserted-by":"crossref","first-page":"647848","DOI":"10.3389\/fneur.2021.647848","article-title":"Associations between white matter hyperintensity burden, cerebral blood flow and transit time in small vessel disease: An updated meta-analysis","volume":"12","author":"Stewart","year":"2021","journal-title":"Front Neurol"},{"issue":"5","key":"2026082507364619500_fcag309-B6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1177\/0271678X16631756","article-title":"Magnetic resonance imaging for assessment of cerebrovascular reactivity in cerebral small vessel disease: A systematic review","volume":"36","author":"Blair","year":"2016","journal-title":"J Cereb Blood Flow Metab"},{"issue":"11","key":"2026082507364619500_fcag309-B7","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1161\/STROKEAHA.123.042656","article-title":"Cerebrovascular reactivity in patients with small vessel disease: A cross-sectional study","volume":"54","author":"Sleight","year":"2023","journal-title":"Stroke"},{"issue":"7","key":"2026082507364619500_fcag309-B8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S1474-4422(19)30079-1","article-title":"Small vessel disease: Mechanisms and clinical implications","volume":"18","author":"Wardlaw","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"2026082507364619500_fcag309-B9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bpa.12224","article-title":"Endothelial cells and human cerebral small vessel disease","volume":"25","author":"Hainsworth","year":"2015","journal-title":"Brain Pathology"},{"issue":"10","key":"2026082507364619500_fcag309-B10","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1161\/STROKEAHA.125.051602","article-title":"Tadalafil treatment in patients with cerebral small vessel disease: The ETLAS-2 randomized clinical trial","volume":"56","author":"\u00d6lmestig","year":"2025","journal-title":"Stroke"},{"key":"2026082507364619500_fcag309-B11","first-page":"100520","article-title":"Cognitive outcomes after tadalafil treatment in patients with cerebral small vessel disease: ETLAS-2 sub-study","volume":"9","author":"\u00d6lmestig","year":"2025","journal-title":"Cereb Circ Cogn Behav"},{"issue":"1","key":"2026082507364619500_fcag309-B12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1186\/s13063-024-08402-4","article-title":"Cerebral blood flow and cognition after 3 months tadalafil treatment in small vessel disease (ETLAS-2): Study protocol for a randomized controlled trial","volume":"25","author":"\u00d6lmestig","year":"2024","journal-title":"Trials"},{"issue":"4","key":"2026082507364619500_fcag309-B13","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1073\/pnas.95.4.1834","article-title":"Calibrated functional MRI: Mapping the dynamics of oxidative metabolism","volume":"95","author":"Davis","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026082507364619500_fcag309-B14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/mrm.10559","article-title":"Arterial transit time imaging with flow encoding arterial spin tagging (FEAST)","volume":"50","author":"Wang","year":"2003","journal-title":"Magn Reson Med"},{"issue":"5","key":"2026082507364619500_fcag309-B15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/mrm.23104","article-title":"A two-stage approach for measuring vascular water exchange and arterial transit time by diffusion-weighted perfusion MRI","volume":"67","author":"St. Lawrence","year":"2012","journal-title":"Magn Reson Med"},{"issue":"16","key":"2026082507364619500_fcag309-B16","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1073\/pnas.96.16.9403","article-title":"Linear coupling between cerebral blood flow and oxygen consumption in activated human cortex","volume":"96","author":"Hoge","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2026082507364619500_fcag309-B17","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1177\/0271678X19874643","article-title":"Comparison of simultaneous arterial spin labeling MRI and 15O-H2O PET measurements of regional cerebral blood flow in rest and altered perfusion states","volume":"40","author":"Puig","year":"2019","journal-title":"J Cereb Blood Flow Metab"},{"issue":"12","key":"2026082507364619500_fcag309-B18","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/alz.12559","article-title":"The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment","volume":"18","author":"Pauls","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2026082507364619500_fcag309-B19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12975-021-00983-5","article-title":"Test\u2013retest reliability of arterial spin labelling for cerebral blood flow in older adults with small vessel disease","volume":"13","author":"Binnie","year":"2022","journal-title":"Transl Stroke Res"},{"key":"2026082507364619500_fcag309-B20","first-page":"100187","article-title":"Testing the cognitive effects of tadalafil. Neuropsychological secondary outcomes from the PASTIS trial","volume":"5","author":"Pauls","year":"2023","journal-title":"Cereb Circ Cogn Behav"},{"issue":"2","key":"2026082507364619500_fcag309-B21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0271678X17747177","article-title":"The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review","volume":"38","author":"Pauls","year":"2018","journal-title":"J Cereb Blood Flow Metab"},{"issue":"11","key":"2026082507364619500_fcag309-B22","doi-asserted-by":"crossref","first-page":"e210008","DOI":"10.1212\/WNL.0000000000210008","article-title":"Association of cerebrovascular reactivity with 1-year imaging and clinical outcomes in small vessel disease: An observational cohort study","volume":"103","author":"Sleight","year":"2024","journal-title":"Neurology"},{"issue":"4","key":"2026082507364619500_fcag309-B23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/23969873231196981","article-title":"Associations between neurovascular coupling and cerebral small vessel disease: A systematic review and meta-analysis","volume":"8","author":"Yang","year":"2023","journal-title":"Eur Stroke J"},{"issue":"7","key":"2026082507364619500_fcag309-B24","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1002\/alz.13874","article-title":"Heterogeneous blood-brain barrier dysfunction in cerebral small vessel diseases","volume":"20","author":"Ying","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"5","key":"2026082507364619500_fcag309-B25","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1002\/mrm.27632","article-title":"Mapping water exchange across the blood-brain barrier using 3D diffusion-prepared arterial spin labeled perfusion MRI","volume":"81","author":"Shao","year":"2019","journal-title":"Magn Reson Med"},{"issue":"7","key":"2026082507364619500_fcag309-B26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2023.1526","article-title":"Isosorbide mononitrate and cilostazol treatment in patients with symptomatic cerebral small vessel disease: The lacunar intervention trial-2 (LACI-2) randomized clinical trial","volume":"80","author":"Wardlaw","year":"2023","journal-title":"JAMA Neurol"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag309\/70634967\/fcag309.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/4\/fcag309\/70634967\/fcag309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/4\/fcag309\/70634967\/fcag309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:37:03Z","timestamp":1787657823000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag309\/8761138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag309","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag309"}}